What drug class is Lovenox (enoxaparin)?
Lovenox (enoxaparin) is a low–molecular-weight heparin (LMWH), an anticoagulant used to prevent and treat blood clots. It works by enhancing the activity of antithrombin, which inhibits clotting factors (especially factor Xa, and also to a lesser extent factor IIa).
Is Lovenox a “heparin” or something different?
Lovenox is heparin-based, but it’s not unfractionated heparin. The “low–molecular-weight” part matters clinically because LMWHs like enoxaparin have more predictable anticoagulant effects and are commonly dosed by weight for many indications.
What is it used for (why people take it)?
Lovenox is commonly prescribed for situations involving clot risk, such as:
- Preventing deep vein thrombosis (DVT) or pulmonary embolism (PE) after surgery or in higher-risk patients
- Treatment of DVT and PE
- Certain acute coronary syndromes (for example, unstable angina or non–ST-elevation myocardial infarction), where it’s used as part of antithrombotic therapy
How is it typically administered?
It is given by injection (subcutaneous is common; intravenous use can apply in some inpatient protocols depending on the indication and clinician guidance).
Where does it show up in drug classifications (common search terms)?
If you’re searching formularies or pharmacy systems, “Lovenox” will usually be filed under terms like:
- Anticoagulant
- Heparin / Low–molecular-weight heparin (LMWH)
- Factor Xa inhibitor class (because factor Xa inhibition is central to its action)
Want the patent/exclusivity angle too?
If your interest is strictly “drug class,” you likely do not need patent data. But if you meant “class” as in market exclusivity/brand status, DrugPatentWatch.com tracks legal/patent information for products like enoxaparin-related drugs. You can check there: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/